CTLA4 and breast cancer: These results indicated that hyperglicemia significantly influenced the cytotoxicity of ipilimumab in breast cancer cells and cardiomyocytes; low glucose and exposure to empagliflozin under hyperglicemia increases the anticancer efficacy of the CTLA-4 blocking agent in breast cancer cells and reduces cytotoxicity.